Downregulation of RGMA by HIF-1A/miR-210-3p axis promotes cell proliferation in oral squamous cell carcinoma

• Published in: Biomedicine & pharmacotherapy Vol. 112; p. 108608
• Main Authors: Lu, Yingjuan, Li, Yingru, Wang, Zhangsong, Xie, Shule, Wang, Qing, Lei, Xinyuan, Ruan, Yi, Li, Jinsong
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01-04-2019; Elsevier
• Subjects: Hypoxia; miRNA; Oral squamous cell carcinoma; Proliferation; Repulsive guidance molecules; GEO; OSCC; IHC; miRNA; Hypoxia; ICAM-1; Oral squamous cell carcinoma; Proliferation; RGMs; NEO1; Repulsive guidance molecules; TCGA
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2019.108608

[Display omitted]
•RGMA extremely decreases in OSCC and correlates with T stages and poor prognosis.•RGMA overexpression in OSCC inhibits cell proliferation, migration and invasion.•RGMA downregulation is regulated by a HIF-1A/miR-210 axis.
Repulsive guidance molecules comprise a group of proteins that play an important role in carcinogenesis through interactions with their receptors, but their function in oral squamous cell carcinoma (OSCC) is unclear. Here, we investigated the potential role of the RGM family members in oral cancer pathogenesis. Our study showed that only RGMA was significantly downregulated in the OSCC tissues analyzed by TCGA and validated this finding in OSCC cells. The decreased expression of RGMA was strongly associated with the T stage and with poor prognosis. The ectopic expression of RGMA significantly inhibited the proliferation of OSCC cells both in vitro and in vivo. Moreover, we confirmed that RGMA was a target of miR-210-3p in OSCC and miR-210-3p overexpression contributed to the acceleration of OSCC growth. Further experiments revealed that HIF1A specifically interacted with the promoter of miR-210-3p and enhanced its expression. In summary, our research indicates that RGMA is regulated by the HIF1A/miR-210-3p axis and inhibits OSCC cell proliferation; thus, in the future, the development of therapies that target the HIF1A/miR-210-3p/RGMA axis may aid in the treatment of aggressive cancers.